Prof. Dr. Andreas Stallmach

Funktionen

• Klinikdirektor

Forschungsgebiete

• Pathogenese und neue therapeutische Ansätze bei chronischen Entzündungen und Malignomen im Gastrointestinaltrakt

Publikationen (ausgewählte 10 aktuelle)

1. Teich, B. Bokemeyer, W. Mohl, J. Walldorf, T. Bruns, C. Schmidt, A. Stallmach, "German IBD study group. Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD", Gut 2016, DOI: 10.1136/gutjnl-2016-313138.
2. Stallmach, C. Langbein, R. Atreya, T. Bruns, A. Dignass, K. Ende, J. Hampe, F. Hartmann, M.F. Neurath, J. Maul, J. C. Preiss, R. Schmelz, B. Siegmund, H. Schulze, N. Teich, U. von Arnim, D. C. Baumgart, C. Schmidt, "Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - A prospective multicenter observational study", Aliment Pharmacol. Ther. 2016, 44, 1199-1212.
3. Leifeld, G. Rogler, A. Stallmach, C. Schmidt, I. Zuber-Jerger, F. Hartmann, M. Plauth, A. Drabik, F. Hofstädter, H. P. Dienes, W. Kruis, "Detect dysplasia study group. White-light or narrow-band imaging colonoscopy in surveillance of ulcerative colitis: A prospective multicenter study", Clin. Gastroenterol. Hepatol. 2015, 13, 1776-1781.
4. Tolstik, C. Marquardt, C. Beleites, C. Matthäus, C. Bielecki, M. Bürger, C. Krafft, O. Dirsch, U. Settmacher, J. Popp, A. Stallmach, "Classification and prediction of HCC tissues by Raman imaging with identification of fatty acids as potential lipid biomarkers", J. Cancer Res. Clin. Oncol. 2015, 141, 407-418.
5.   Lautenschläger, C. Schmidt, D. Fischer, A. Stallmach, "Drug delivery strategies in the therapy of inflammatory bowel disease", Adv. Drug Deliv. Rev. 2014, 71, 58-76.
6. Bruns, H. W. Zimmermann, A. Stallmach, "Risk factors and outcome of bacterial infections in cirrhosis", World J. Gastroenterol. 2014, 20, 2542-2554.
7. Schmidt, C. Lautenschläger, B. Petzold, Y. Sakr, G. Marx, A. Stallmach, "Confocal laser endomicroscopy reliably detects sepsis-related and treatment-associated changes in intestinal mucosal microcirculation", Br. J. Anaesth. 2013, 111, 996-1003.
8. Lautenschläger, C. Schmidt, C. M. Lehr, D. Fischer, A. Stallmach, "PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease", Eur. J. Pharm. Biopharm. 2013, 85, 578-86.
9. Schmidt, C. Lautenschläger, E. M. Collnot, M. Schumann, C. Bojarski, J. D. Schulzke, C. M. Lehr, A. Stallmach, "Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: A first in vivo study in human patients", J. Control. Release 2013, 165, 139-145.
10. T. Dietzel, H. Richert, S. Abert, U. Merkel, M. Hippius, A. Stallmach, "Magnetic active agent release system (MAARS): Evaluation of a new way for a reproducible, externally controlled drug release into the small intestine", J. Control. Release 2012, 161, 722-727.